Akums Drugs & Pharmaceuticals Ltd. has announced robust financial results for Q4 FY26 and the full fiscal year ended March 31, 2026. The company reported a significant 135% year-on-year growth in Adj PAT for the quarter, alongside healthy revenue expansion. Driven by strong performance in its CDMO segment and strategic global milestones, the Board has recommended a total dividend of ₹3 per equity share, comprising a final and special dividend.
Financial Highlights
For the quarter ended March 31, 2026, Akums reported an operating revenue of ₹1,158 crore, a 9.7% increase compared to the same period last year. Profitability saw a substantial boost, with Adj EBITDA rising 61.6% to ₹152 crore, and Adj PAT soaring to ₹83 crore from ₹35 crore in Q4 FY25. On an annual basis, FY26 revenue reached ₹4,359 crore, while Adj PAT grew by 27.3% to ₹276 crore.
Segment Performance
The Contract Development and Manufacturing Organisation (CDMO) business emerged as the primary growth driver, contributing ₹952 crore in revenue for the quarter with an improved EBITDA margin of 14.4%. While the Domestic Branded Formulations business remained stable, Trade generics achieved a turnaround, reporting a positive EBITDA of ₹1.4 crore for the quarter. The API business continued to face pricing pressures, though the company noted a marginal reduction in annual EBITDA losses.
Global Expansion and Dividends
During the fiscal year, Akums made significant strides in its international footprint, including the first commercial supply of formulations to Europe and new regulatory approvals for its Oral Solids, Oral Liquids, and injectable facilities. The company also broke ground on a new pharmaceutical plant in Zambia. Reflecting the strong annual performance, the Board has recommended a final dividend of ₹1 per share and a special dividend of ₹2 per share, totaling ₹3 per equity share.
Source: BSE
